Being listed among the Fast 500 identifies Bacterin as an innovative leader in its sector. Companies listed in the Deloitte Technology Fast 500 rankings are exemplary companies that are, through innovation, spurring growth in a difficult market.
“This year’s list is a who’s who of companies behind the most exciting and innovative products and services in the technology space,” said Eric Openshaw, a technology, media and telecommunications leader and vice chairman of Deloitte LLP. “We congratulate the Fast 500 companies and look forward to what they do next.”
Winners of the 2013 award were chosen based on their percentage fiscal year revenue growth between 2008 and 2012.
Bacterin is engaged in developing, manufacturing, and marketing biologics products to domestic and international markets. The company’s proprietary methods optimize the growth factors in human allografts to stimulate bone, subchondral repair, and dermal growth. Bacterin’s products are used in various applications, including enhancing fusion in spine surgery, relieving back pain, promoting bone growth in foot and ankle surgery, and promoting cranial healing after neurosurgery and subchondral repair in knee and other joint surgeries. The company’s medical device division develops, employs, and licenses coatings for a variety of medical device applications.
For more information, visit www.bacterin.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
No comments:
Post a Comment